IL5 and allergic asthma: For example, dupilumab, an anti‐interleukin 4 (IL4) receptor alpha monoclonal antibody, has already been approved for the treatment of atopic dermatitis and allergic asthma, while mepolizumab, an anti‐IL5 monoclonal antibody, has already been approved for allergic asthma.78